European collaboration in trials of new agents for children with cancer

European Journal of Cancer

Volumn 40, Issue 12, 2004, Pages 1886-1892

  Ablett, S ^a   Doz, F ^b   Morland, B ^c   Vassal, G ^d  

^a UKCCSG Data Centre   (United Kingdom)

^b INSTITUT CURIE   (France)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Childhood cancer; International collaboration; New agents; Phase I II studies

Indexed keywords

ANTIINFECTIVE AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; DAUNORUBICIN; ETOPOSIDE; IMATINIB; IRINOTECAN; NOLATREXED; OXALIPLATIN; PACLITAXEL; RASBURICASE; TEMOZOLOMIDE; THIOTEPA; VALSPODAR;

CANCER THERAPY; CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG MEGADOSE; EUROPE; FRANCE; HUMAN; ORGANIZATION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 3843070167     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.05.011     Document Type: Article

References (18)

1. Schilsky R.L. End-points in cancer clinical trials and the drug approval process. Clin. Cancer Res. 8:2002;935-938
2. Estlin EJ, Lashford L, Ablett S, Price L et al. On behalf of the UKCCSG Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 1998,78,652-661
3. Smith M., Bernstein M., Bleyer A., Borsi J.D., Ho P., Lewis I.J., et al. Conduct of phase I trials in children with cancer. J. Clin. Oncol. 16(3):1998;966-978
4. Pein F., Pinkerton R., Rubie H., Stevens M., Pearson A.D.J., et al. A phase I trial of Oral Amdray (PSC 833) in combination with a rapid schedule of intravenous (IV) etoposide in children with relapsing and/or refractory solid tumours. Med. Paediatr. Oncol. 33(3):1999;155
5. Estlin E.J., Pinkerton C.R., Lewis I.J., Lashford L., McDowell H., et al. A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom children's cancer study group investigation. Brit. J. Cancer. 84(1):2001;11-18
6. Vassal G., Doz F., Frappaz D., Imadalou K., Sicard E., Santos A., et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J. Clin. Oncol. 21(20):2003;3844-3852
7. Lowis S., Lewis I.J., Elsworth A., Ablett S., Robert J., Frappaz D. Cardiac toxicity may limit the usefulness of DaunoXome - results of a phase I study in children with relapsed or resistant tumours - a UKCCSG/SFOP study. Med. Paediatr. Oncol. 39(4):2002;250
8. Doz F., Gentet J.-C., Pein F., Frappaz D., et al. Phase I trial and pharmacological study of a 3-h paclitaxel infusion in children with refractory solid tumours: a SFOP study. Brit. J. Cancer. 84:2001;604-610
9. Geoerger B., Doz F., Mayer M., Rubie H., et al. Dose finding and pharmacokinetic study of weekly oxaliplatin in pediatric solid malignancies. Proc. Am. Soc. Clin. Oncol. 22:2003;810
10. Lashford L.S., Thiesse P., Jouvet A., Jaspan T., Couanet D., Griffiths P.D., et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society of Paediatric Oncology Intergroup Study. J. Clin. Oncol. 20:2002;4684-4691
11. Vassal G., Doz F., Frappaz D., Gentet J.-C., et al. A phase II study of irinotecan (CPT-11) in children with relapsed or refractory neuroblastoma. Med. Paediatr. Oncol. 39(4):2002;257
12. Vassal G., Doz F., Pichon F., Frappaz D., et al. A phase II study of irinotecan (CPT-11) in children and adolescents with relapsed or refractory rhabdomyosarcoma. Med. Paediatr. Oncol. 39(4):2002;240
13. Vassal G., Chastagner P., Doz F., Frappaz D., Gentet J.-C., et al. A phase II study of irinotecan in children with relapsed or refractory CNS tumours (medulloblastoma and PNET). Proc. Am. Soc. Clin. Oncol. 22:2003;805
14. Thiesse Ph, Jaspan T, Couanet D, Bracard S, Neuenschwander S, Griffiths PD. Au nom des comites d'expertise radiologique de la Societe Francaise d'Oncologie Pediatrique (SFOP) et de l'United Kingdom Children's Cancer Study Group (UKCCSG). Un protocole d'imagerie des tumours cerebrales de l'enfant. J Radiol 2001, 82, 11-16
15. O'Quigley J. Continual reassessment method in cancer clinical trials. Crowley J. Handbook of statistics in clinical oncology. 2001;35-72 Marcel Dekker, New York
16. Geoerger B., Vassal G., Doz F., Raquin M.A., et al. Dose finding and O 6-alkyltransferase depletion of cisplatin combined with temozolomide in pediatric solid malignancies. Proc. Am. Soc. Clin. Oncol. 21:2002;107a
17. Steinbrook R. Testing medications in children. N. Engl. J. Med. 347(18):2002;1462-1470
18. Hirschfeld S., Ho P.T., Smithi M., Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J. Clin. Oncol. 21:2003;1066-1073